Please login to the form below

Not currently logged in

Merck ends HIV drug study

Merck is to end its study investigating once-daily Isentress for patients with HIV-1 after it failed to improve on a twice-daily version

Merck is to end its study investigating once-daily Isentress (raltegravir) for patients with HIV-1 after the drug failed to improve on an already approved twice-daily version in a phase III trial.

The trial evaluated the safety and efficacy of an investigational once-daily 800mg dose of the drug against the approved twice-daily 400mg dose, each in combination with a once-daily dose of emtricitabine and tenofovir disoproxil fumarate, in adult treatment-naïve HIV-1-infected patients.

Of the patients taking the once-daily does, 83.2 per cent achieved undetectable viral levels, compared to 88.9 per cent of patients in the twice-daily group. This difference, however, did not meet the pre-defined statistical criteria for non-inferiority.

Drug safety was found to be similar in both regimens, and consistent with current labelling for Isentress.

The 400mg version of the drug is currently the only approved integrase inhibitor for the treatment of HIV-1. It works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme.

Merck said it is notifying clinical investigators of the decision to cancel the trial this week, with a recommendation that patients enrolled in the once-daily dosing arm of the study be switched to Isentress twice daily.

30th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...
30 Women Leaders in UK Healthcare (part 2)
Part two of our list of thirty women leaders 11-20...